HealthTech acquires Acuitec

Editorial Staff | | Health Exec | Digital Transformation

HealthTech Holdings has acquired integrated perioperative solutions developer, Acuitec. 

Acuitec’s flagship product, VPIMS (Vigilant Perioperative Information Management Solution), is a technology for the perioperative setting that scales to facilities of all sizes. VPIMS includes scheduling, preference cards, nurse documentation, case management, reports, anesthesia charting and mobile capabilities. Acuitec was originally formed as a partnership with Vanderbilt University Medical Center in Nashville, Tenn., for the purpose of commercializing their products, VPIMS and Vigilance, a remote presence and clinician support application allowing multiple cases to be monitored at the same time.

Acuitec will operate as an independent business line within HealthTech, and its technology will be integrated into the EHR from HMS. HealthTech will retain all Acuitec employees and its Birmingham, Ala., headquarters with Lionel Tehini continuing to serve as Acuitec’s president.

 

Editorial Staff

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.